Approval of Adagrasib for KRAS G12C–Mutated NSCLC Will ‘Open Up Another Therapeutic Option’, Says Expert

Video

Alexander Spira, MD, PhD, FACP, of the Virginia Cancer Specialists, discusses how the FDA approval of adagrasib for KRAS G12C–mutated non–small cell lung cancer can provide benefit for this patient population.

In an interview with CancerNetwork®, Alexander Spira, MD, PhD, FACP, a medical oncologist and co-director of the Virginia Cancer Specialists Research Institution, as well as the director of the Thoracic and Phase I Program and clinical assistant professor at Johns Hopkins University, spoke about the FDA’s accelerated approval of adagrasib (Krazati) for the treatment of patients with non–small cell lung cancer (NSCLC) harboring KRAS G12C mutations.

According to Spira, the approval of adagrasib allows for another treatment option for patients with KRAS G12C–mutated NSCLC who may tolerate the agent more than other approved therapies such as sotorasib (Lumakras). He also described other benefits of the agent in terms of managing central nervous system (CNS) metastases.

Transcript:

The approval of adagrasib for KRAS G12C–mutated non–small cell lung cancer will open up another therapeutic option. As you know, we have sotorasib already approved, but [these agents] do have slightly different toxicity profiles. It's always good to have more than one class because some people do tolerate one better than the other one. It also verifies the fact that this is now an actual genetic mutation for which we've been trying to find drugs for the better part of a quarter century. The other thing that is that adagrasib does have some [central nervous system] CNS activity, and these patients do have a predilection to CNS metastases. Hopefully, it could be used in that situation for the right patients, although this would likely not be on the label.

Reference

FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC. News release. FDA. December 12, 2022. Accessed December 13, 2022. https://bit.ly/3UUVphS

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.
It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.
Related Content